| Molecular Formula | C29H33NO5 |
| Molar Mass | 475.576 |
| Density | 1.182±0.06 g/cm3(Predicted) |
| Boling Point | 630.2±55.0 °C(Predicted) |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml) |
| Appearance | solid |
| Color | White |
| pKa | 2.34±0.20(Predicted) |
| Storage Condition | -20℃ |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Physical and Chemical Properties | Bioactivity BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is a PD-1/PD-L1 interacting small molecule compound inhibitor with an IC50 of 6 nM. |
| Target | Target Value PD-1/PD-L1 interaction (Cell-free assay) 0.006 μM |
| In vitro study | Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy. Cell Cytotoxicity Assay Cell Line: NK cells and HepG2 cells Concentration: 1 μM Incubation Time: 3 days Result: Disturbed the interaction between PD-1 and PD-L1. |
| In vivo study | BMS-1 (500 μg/mL; 100 μL; i.p.) significantly slows down tumor growth and prolongs the survival rates in BALB/c mice. Animal Model: BALB/c mice Dosage: 500 μg/mL; 100 μL Administration: I.p. Result: Administration significantly slowed down tumor growth and prolonged the survival rates. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.103 ml | 10.514 ml | 21.027 ml |
| 5 mM | 0.421 ml | 2.103 ml | 4.205 ml |
| 10 mM | 0.21 ml | 1.051 ml | 2.103 ml |
| 5 mM | 0.042 ml | 0.21 ml | 0.421 ml |